关键词:

非小细胞肺癌, 涎液化糖链抗原-6, PD-1抑制剂, 免疫性肺炎

Abstract:

Objective　To analyze the relationship between serum Krebs Von den Lungen-6 (KL-6) level and programmed death receptor-1 (PD-1) associated immune pneumonia in patients with non-small cell lung cancer (NSCLC). Methods　A total of 72 patients with NSCLC admitted to Luoyang Central Hospital from January 2021 to December 2022 were selected, who were treated with PD-1 inhibitor for 1 month. There were 43 males and 29 females, aged 63-75 (68.54±3.83) years. Serum KL-6 level was detected before and after 1 month of treatment. The occurrence of PD-1 associated immune pneumonia was observed within 3 months after treatment, and the relationship between the occurrence of PD-1 associated immune pneumonia and serum KL-6 level before and after treatment was compared. t test, χ² test, and point two-column correlation analysis were used. Results　After the patients were treated with PD-1 inhibitor, 5 cases developed associated immune pneumonia, with an incidence of 6.94%. The serum KL-6 level in the occurrence group was (1 518.72±263.67) U/ml before treatment and (1 185.36±207.15) U/ml after treatment, which were higher than those in the non-occurrence group [(1 064.01±185.09) U/ml and (879.44±112.06) U/ml], with statistically significant differences (both P<0.05). By point two-column correlation analysis, the occurrence of PD-1 associated immune pneumonia was positively correlated with serum KL-6 level before and after treatment (r=0.524 and 0.551, both P<0.001). Conclusion　During PD-1 inhibitor therapy, the occurrence of PD-1 associated immune pneumonia is positively correlated with pre- and post-treatment serum KL-6 levels, and patients with higher serum KL-6 level before treatment are more likely to develop associated immune pneumonia after treatment.

Key words:

Non-small cell lung cancer, Krebs Von den Lungen-6, PD-1 inhibitor, Immune pneumonitis